Practice Effects Predict Cognitive Outcome in Amnestic Mild Cognitive Impairment

Department of Neurology, University of Utah, Salt Lake City, 84108, USA.
The American journal of geriatric psychiatry: official journal of the American Association for Geriatric Psychiatry (Impact Factor: 3.35). 11/2011; 19(11):932-9. DOI: 10.1097/JGP.0b013e318209dd3a
Source: PubMed

ABSTRACT Practice effects on cognitive tests have been shown to further characterize patients with amnestic mild cognitive impairment (aMCI) and may provide predictive information about cognitive change across time. We tested the hypothesis that a loss of practice effects would portend a worse prognosis in aMCI.
Longitudinal, observational design following participants across 1 year.
Community-based cohort.
Three groups of older adults: 1) cognitively intact (n = 57), 2) aMCI with large practice effects across 1 week (MCI + PE, n = 25), and 3) aMCI with minimal practice effects across 1 week (MCI - PE, n = 26).
Neuropsychological tests.
After controlling for age and baseline cognitive differences, the MCI - PE group performed significantly worse than the other groups after 1 year on measures of immediate memory, delayed memory, language, and overall cognition.
Although these results need to be replicated in larger samples, the loss of short-term practice effects portends a worse prognosis in patients with aMCI.

1 Bookmark
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Although neuropsychologists are frequently asked to evaluate cognitive change in a patient, this can be a complex determination. Using data from 167 non-demented older adults tested twice across one week, the current study sought to provide a variety of reliable change indices for a brief battery of commonly used neuropsychological measures. Statistically significant improvements were observed on seven of nine scores examined over this short retest interval, with the largest changes occurring on memory measures. Information is provided on simple discrepancy scores, standard deviation index, reliable change index (with and without correcting for practice effects), and standardized regression based change formulae for each cognitive score. Even though a one-week retesting interval is a less typical clinical scenario, these results may give clinicians and researchers more options for assessing short-term change in a variety of settings.
    The Clinical Neuropsychologist 06/2014; DOI:10.1080/13854046.2014.920923 · 1.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We present longitudinal clinical, cognitive, and neuroimaging data from a 63-year-old woman who enrolled in research as a normal control and evolved posterior cortical atrophy (PCA) over 5 year follow-up. At baseline she reported only subtle difficulty driving and performed normally on cognitive tests, but already demonstrated atrophy in left visual association cortex. With follow-up she developed insidiously progressive visuospatial and visuoperceptual deficits, correlating with progressive atrophy in bilateral visual areas. Amyloid PET was positive. This case tracks the evolution of PCA from the prodromal stage, and illustrates challenges to early diagnosis as well as the utility of imaging biomarkers.
    Neurocase 12/2013; DOI:10.1080/13554794.2013.860176 · 1.38 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Clinical trials in Alzheimer disease are moving toward prevention studies in prodromal individuals with amyloid burden. However, methods are needed to identify individuals expected to be amyloid positive for these studies to be feasible and cost-effective. The current study sought to determine whether short-term practice effects on cognitive tests can identify those with notable uptake on amyloid imaging. Twenty-five, nondemented older adults (15 cognitively intact, 10 with mild cognitive impairment) underwent amyloid imaging through F-flutemetamol and 2 cognitive testing sessions across 1 week to determine practice effects on a visual memory test. Results indicated that, whereas F-flutemetamol uptake showed little association with baseline performance on a visual memory test (r=-0.04, P=0.85), it was significantly correlated with practice effects across 1 week on that same memory measure (r=-0.45, P=0.02), with greater uptake being associated with lower practice effects. The odds ratio of notable F-flutemetamol uptake was 5 times higher in individuals with low practice effects compared with high practice effects. Although these preliminary results need to be replicated in larger samples, short-term practice effects on cognitive tests may provide an affordable screening method to identify individuals who are amyloid positive, which could enrich samples for preventative clinical trials in Alzheimer disease.
    Alzheimer disease and associated disorders 03/2014; DOI:10.1097/WAD.0000000000000021 · 2.88 Impact Factor

Full-text (2 Sources)

Available from
May 29, 2014